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Biological knowledge of infectious diseases and other diseases for which vaccines may provide therapeutic 
benefits, such as cancer, is growing at an accelerated pace.  The implications of this knowledge are improved 
stratification of diseases, possibilities for personalized treatments, and explicit understanding of protective 
immune responses to be elicited by vaccines.  With this knowledge, it is becoming increasingly feasible to 
engineer vaccines for specific responses rather than relying on empirical development.   Despite this potential, 
the challenge of routine, low-cost manufacturing of vaccines creates a barrier to transforming health care in both 
high- and low-resource countries.  Vaccines today do not benefit from well-defined, platform-like processes for 
manufacturing, and concepts such as continuous bioprocessing remain largely within the realm of 
biopharmaceutical products.   
 
The InSCyT platform is an advanced prototype manufacturing system that provides integrated and automated 
production and purification of multiple protein therapeutics.  The system allows end-to-end manufacturing of 
100's to 10,000's of doses of recombinant protein drugs in days.  It uses a state-of-the-art approach to process 
design and implementation that takes advantage of a fast-growing, tractable microbial host (Pichia pastoris) and 
continuous processing for automated, hands-free purification through simple 2- or 3-stage chromatographic 
processes.  The platform design is highly modular, allowing facile process development and process 
deployment for multiple products.  This feature emerges from the predictable behavior of the fermentation and 
cell culture fluids, and rapid cloning of new molecules, that together facilitate fast development of entirely new 
processes in weeks.  To date, this system has been used to reproducibly manufacture high-quality human 
growth hormone (hGH), granulocyte-colony stimulating factor (G-CSF), and interferon-α2b (IFN-α2b) in an 
integrated, automated manner.  The speed of production using the InSCyT prototype allows volumetric 
productivities that compare favorably to those for mammalian-based production. 
 
This talk will outline the design and capabilities of the InSCyT system, demonstrate the quality of biologic drugs 
made to date on the system, and outline opportunities for advancing the platform to provide new capabilities in 
manufacturing recombinant proteins for use in vaccines.  As part of a Gates Foundation-funded Grand 
Challenge called ULTRA, we have begun to assess the feasibility of manufacturing millions of doses of a 
trivalent recombinant rotavirus vaccine annually on a small-scale production system like InSCyT.  Integrated 
bioprocessing enabled by systems such as these could offer potential advantages for routine production in local 
regions with minimal infrastructure, and for democratization of manufacturing capacity for new vaccine concepts 
and personalized treatments in cancer. 
 
